These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35765699)

  • 1. Grey matter atrophy in patients with benign multiple sclerosis.
    Niiranen M; Koikkalainen J; Lötjönen J; Selander T; Cajanus A; Hartikainen P; Simula S; Vanninen R; Remes AM
    Brain Behav; 2022 Jul; 12(7):e2679. PubMed ID: 35765699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
    Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enlarged choroid plexus in multiple sclerosis is associated with increased lesion load and atrophy in white matter but not gray matter atrophy.
    Akaishi T; Fujimori J; Nakashima I
    Mult Scler Relat Disord; 2024 Feb; 82():105424. PubMed ID: 38181695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis.
    Gonçalves LI; Dos Passos GR; Conzatti LP; Burger JLP; Tomasi GH; Zandoná MÉ; Azambuja LS; Gomes I; Franco A; Sato DK; Becker J
    Mult Scler Relat Disord; 2018 Feb; 20():154-158. PubMed ID: 29414290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis.
    Wang X; Zhu Q; Yan Z; Shi Z; Xu Y; Liu Y; Li Y
    Mult Scler Relat Disord; 2023 Jul; 75():104740. PubMed ID: 37146422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
    Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.
    Engl C; Tiemann L; Grahl S; Bussas M; Schmidt P; Pongratz V; Berthele A; Beer A; Gaser C; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
    J Neurol; 2020 Aug; 267(8):2307-2318. PubMed ID: 32328718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
    Kalinin I; Makshakov G; Evdoshenko E
    AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
    Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Bussas M; Grahl S; Pongratz V; Berthele A; Gasperi C; Andlauer T; Gaser C; Kirschke JS; Wiestler B; Zimmer C; Hemmer B; Mühlau M
    Mult Scler; 2022 May; 28(6):900-909. PubMed ID: 34591698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
    Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
    AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW
    J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.